Quoin Pharmaceuticals (QNRX) Non-Current Debt (2020 - 2022)

Quoin Pharmaceuticals has disclosed Non-Current Debt across 3 years of filings, most recently posting $3.5 million for Q4 2022.

• In Q4 2022, Non-Current Debt fell 14.55% year-over-year to $3.5 million; the TTM figure through Dec 2022 stood at $3.5 million (down 14.55% YoY), while the FY2022 annual figure was $3.5 million, down 14.55% from the prior year.
• Non-Current Debt came in at $3.5 million for Q4 2022 at Quoin Pharmaceuticals, down from $4.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $4.1 million in Q4 2021 to a low of $1.2 million in Q4 2020.
• Average Non-Current Debt over 3 years is $3.0 million, with a median of $3.5 million recorded in 2022.
• Year-over-year, Non-Current Debt soared 239.87% in 2021 and decreased 14.55% in 2022.
• Over 3 years, Non-Current Debt stood at $1.2 million in 2020, then soared by 239.87% to $4.1 million in 2021, then declined by 14.55% to $3.5 million in 2022.
• Per Business Quant data, the three most recent Non-Current Debt figures were $3.5 million in Q4 2022, $4.1 million in Q4 2021, and $1.2 million in Q4 2020.